𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Endpoints in cancer clinical trials: is there a need for measuring quality of life?

✍ Scribed by Ronald Feld


Publisher
Springer-Verlag
Year
1995
Tongue
English
Weight
456 KB
Volume
3
Category
Article
ISSN
0941-4355

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


SUMMARY MEASURES AND STATISTICS FOR COMP
✍ DIANE L. FAIRCLOUGH πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 457 KB πŸ‘ 3 views

Assessment of health related quality of life (QOL) has become an important endpoint in many clinical trials of cancer therapy. Most of these studies entail multiple QOL scales that are assessed repeatedly over time. As a result, the problem of multiple comparisons is a primary analytic challenge wit

Statistical analysis of quality of life
✍ Andrea B. Troxel; Diane L. Fairclough; Desmond Curran; Elizabeth A. Hahn πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 255 KB πŸ‘ 3 views

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud

Missing quality of life data in cancer c
✍ JΓΌrg Bernhard; David F. Cella; Alan S. Coates; Lesley Fallowfield; Patricia A. G πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 173 KB πŸ‘ 2 views

Measurement of quality of life (QOL) in cancer clinical trials has increased in recent years as more groups realize the importance of such endpoints. A key problem has been missing data. Some QOL data may unavoidably be missing, as for example when patients are too ill to complete forms. Other impor

Why are missing quality of life data a p
✍ Diane L. Fairclough; Harriet F. Peterson; Victor Chang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 116 KB πŸ‘ 3 views

Assessment of health related quality of life has become an important endpoint in many cancer clinical trials. Because the participants of these trials often experience disease and treatment related morbidity and mortality, non-random missing assessments are inevitable. Examples are presented from se